Latest Conference Articles

August 27th 2022, 1:53pm

International Myeloma Society Annual Meeting

Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects that may arise with belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

August 27th 2022, 12:46pm

International Myeloma Society Annual Meeting

Treatment with standard-of-care isatuximab in patients with relapsed/refractory multiple myeloma is being evaluated in a real-world trial,

August 26th 2022, 9:54pm

International Myeloma Society Annual Meeting

Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.

August 26th 2022, 9:45pm

International Myeloma Society Annual Meeting

The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.

August 26th 2022, 9:39pm

International Myeloma Society Annual Meeting

The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.

August 26th 2022, 9:24pm

International Myeloma Society Annual Meeting

Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.

August 26th 2022, 8:04pm

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

August 26th 2022, 8:00pm

Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.

August 26th 2022, 7:31pm

International Myeloma Society Annual Meeting

Induction and consolidation therapy with a combination comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.

August 26th 2022, 7:25pm

International Myeloma Society Annual Meeting

Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.

August 26th 2022, 6:30pm

International Myeloma Society Annual Meeting

Isatuximab-containing regimens displayed favorable toxicity in patients with relapsed/refractory multiple myeloma in a real-world study.

August 26th 2022, 6:14pm

International Myeloma Society Annual Meeting

Patient outcomes across the multiple myeloma landscape have vastly improved with the approval of multiple agents in the treatment armementarium, such as belantamab mafodotin-blmf, selinexor, and ciltacabtagene autoleucel.

August 26th 2022, 5:39pm

International Myeloma Society Annual Meeting

The addition of ixazomib to daratumumab, pomalidomide, and dexamethasone has elicited deep and durable response rates with a manageable safety profile as salvage therapy in patients with relapsed/refractory multiple myeloma.

August 25th 2022, 11:20pm

International Myeloma Society Annual Meeting

Patients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.

August 13th 2022, 10:00am

ESMO Gastrointestinal Cancers Congress

The dual immunotherapy combination comprised of nivolumab given at 1 mg/kg and ipilimumab given at 3 mg/kg provided durable responses and long-term survival benefit in patients with advanced hepatocellular carcinoma following treatment with sorafenib.

August 12th 2022, 6:30pm

ESMO Gastrointestinal Cancers Congress

Recent data highlight the value of the newly approved indications for nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma.

August 12th 2022, 4:30pm

ESMO Gastrointestinal Cancers Congress

Pembrolizumab monotherapy continued to demonstrate durable antitumor activity with promising overall survival in patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib, according to updated data from cohort 1 of the phase 2 KEYNOTE-224 trial.

August 12th 2022, 4:28pm

ESMO Gastrointestinal Cancers Congress

Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.

August 12th 2022, 3:00pm

ESMO Gastrointestinal Cancers Congress

After HER2 was established as an actionable target in gastric cancer, its amplification has become a key biomarker of interest for other gastrointestinal cancers.

August 9th 2022, 9:36pm

IASLC World Conference on Lung Cancer

Treatment with durvalumab and concurrent radiotherapy provided a significant benefit in progression-free survival in patients with locally advanced non–small cell lung cancer, meeting the primary end point of the phase 2 DOLPHIN trial.